AtCor Medical - News 2009

AtCor Medical today announced the publication of a key National Institutes of Health (NIH)-funded study using SphygmoCor in the Journal of the American College of Cardiology (JACC). The NIH is the United States government’s medical research agency.

Please click here to view the ASX/media release

Appendix 3B

28 October 2009

Please click here to view the ASX/media release

2009 Annual General Meeting - CEO's Presentation

21 October 2009

Please click here to view the ASX/media release

2009 Annual General Meeting - Chairman’s Address

21 October 2009

Please click here to view the ASX/media release

First Quarter Report - Appendix 4C

21 October 2009

AtCor Medical today released its quarterly cash flow report for the period ending 30 September 2009.

Please click here to view the ASX/media release

ASX Preliminary Year End Information 2009

21 August 2009

AtCor Medical today released its 2009 Preliminary Year End Information.

Please click here to view the ASX/media release

Record Financial Results

23 July 2009

AtCor Medical today announced unaudited preliminary results for FY2009, which included sales of $11.2 million, an increase of 74% over the prior period and in line with management guidance.

Please click here to view the ASX/media release

Fourth Quarter Report - Appendix 4C

23 July 2009

AtCor Medical today released its quarterly cash flow report for the period ending 30 June 2009.

Please click here to view the ASX/media release

AtCor Medical Debuts WISDOM System - Allows Instant, Remote Review of Central Blood Pressure Test Results in Clinical Trials

4 June 2009

AtCor Medical today announced the introduction of the WISDOM system, a secure data transfer and storage network that links the company, clinical trial sites and its pharmaceutical and medical device clients.

Please click here to view the media release

70% Sales Growth in FY09 Expected

19 May 2009

AtCor Medical today announced that it has increased guidance for FY2009 sales revenue to more than $11 million, up from $10 million anticipated in February 2009. This represents an increase of 70% over FY2008 sales.

Please click here to view the ASX/media release

Third Quarter Report - Appendix 4C

23 April 2009

AtCor Medical today released its quarterly cash flow report for the period ending 31 March 2009.

Please click here to view the ASX/media release

US$0.6 Million New Pharmaceutical Trial Contract - Over US$7.9 Million New Contracts in Past 11 Months

20 April 2009

AtCor Medical today announced that it has signed a new contract to supply SphygmoCor systems and clinical trial support services to a leading international pharmaceutical company. This contract is with an existing client and has a minimum value of US$579,000. The contract brings the total value of US pharmaceutical trial contracts secured over the past 11 months to US$7.9 million.

Please click here to view the ASX/media release

SphygmoCor Shows Drug Lowers Blood Pressure in Pre-Eclampsia Patients - Follows Earlier Study Demonstrating its Accuracy in Predicting Pre-Eclampsia

16 April 2009

AtCor Medical today announced that a new study which used the company’s SphygmoCor system to measure central blood pressure and arterial stiffness non-invasively, has shown important drug effects in pregnant women with pre-eclampsia that could not be detected with standard blood pressure monitoring.

Please click here to view the ASX/media release

US$0.8 Million New Pharmaceutical Trial Contracts - Over US$7.3 Million New Contracts in Past 10 Months

15 April 2009

AtCor Medical today announced that it has signed two new contracts to supply SphygmoCor systems and clinical trial support services to leading international pharmaceutical companies. These contracts are with existing clients and have a minimum value of US$635,000 and US$200,000 respectively. They bring the total value of US pharmaceutical trial contracts secured over the past 10 months to US$7.3 million.

Please click here to view the ASX/media release

New Application for AtCor’s SphygmoCor Technology - Study Indicates SphygmoCor Predicts Major Cause of Maternal and Foetal Mortality

31 March 2009

AtCor Medical today announced that a new study has indicated a further application for its SphygmoCor technology. The study showed that AtCor’s SphygmoCor system can predict the development of pre-eclampsia, which occurs in 3-5 per cent of all pregnancies and is a leading cause of maternal and foetal mortality and pre-term delivery.

Please click here to view the ASX/media release

Investor Presentation

10 March 2009

AtCor Medical today released its investor presentation for 2009 titled "Delivering on Commitments, Driving Sustainability".

Please click here to view the ASX/media release

AtCor Reports Maiden Profit for First Half

19 February 2009

AtCor Medical today announced a maiden profit after tax of $180,477 for H1 2009 (H1 2008: $1,678,798 loss). Sales were $5.4 million, a 76% increase over H1 2008 and a record for the company. On a constant currency basis, sales increased by 64% over H1 2008.

Please click here to view the ASX/media release

AtCor Releases Half Year Results

19 February 2009

AtCor Medical today released its H1 FY2009 results showing a maiden profit after tax for the period.

Please click here to view the ASX/media release

US $0.860m New Pharmaceutical & Biotech Trial Contracts - Over US $6.5m New Contracts in Past 8 Months

28 January 2009

AtCor Medical today announced that it has signed new agreements to supply SphygmoCor® systems and clinical trial support services to a US biotech company and a leading international pharmaceutical company. The minimum total value of the contracts is US $650,000 and US $210,000 respectively. These new orders bring the minimum total value of pharmaceutical trial contracts secured by AtCor in the past eight months to over US $6.5 million.

Please click here to view the ASX/media release

H1 Sales Surge 76% - AtCor Upgrades Guidance for FY2009

21 January 2009

AtCor Medical today announced unaudited H1 FY2009 sales of $5.4 million, a 76% increase over H1 FY2008 and a record for the company. On a constant currency basis, sales increased 64% over the previous corresponding period (pcp).

Please click here to view the ASX/media release

Second Quarter Report - Appendix 4C

21 January 2009

AtCor Medical today released its quarterly cash flow report for the period ending 30 December 2008.

Please click here to view the ASX/media release